Drug Resistance in Leishmania Parasites 2018
DOI: 10.1007/978-3-319-74186-4_13
|View full text |Cite
|
Sign up to set email alerts
|

Bioinformatics in Leishmania Drug Design

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 105 publications
0
1
0
Order By: Relevance
“…Prospects for developing an effective leishmaniasis vaccine are not immediate and disease control is based primarily on chemotherapeutic treatment, although the arsenal of available drugs is reduced and with significant associated toxicity; vector control is problematic generating environmental risk; comorbidity with HIV is increasing; and finally, almost all endemic regions exhibit a growing incidence of therapeutic failure [ 11 , 12 , 13 , 14 ]. Consequently, the design of more effective and safer therapeutic alternatives has become an extraordinary and urgent need [ 15 , 16 , 17 ]. Meanwhile, there is a delay in the development of new drugs, mainly due to the lack of economic stimuli that this disease represents for the pharmaceutical companies.…”
Section: Introductionmentioning
confidence: 99%
“…Prospects for developing an effective leishmaniasis vaccine are not immediate and disease control is based primarily on chemotherapeutic treatment, although the arsenal of available drugs is reduced and with significant associated toxicity; vector control is problematic generating environmental risk; comorbidity with HIV is increasing; and finally, almost all endemic regions exhibit a growing incidence of therapeutic failure [ 11 , 12 , 13 , 14 ]. Consequently, the design of more effective and safer therapeutic alternatives has become an extraordinary and urgent need [ 15 , 16 , 17 ]. Meanwhile, there is a delay in the development of new drugs, mainly due to the lack of economic stimuli that this disease represents for the pharmaceutical companies.…”
Section: Introductionmentioning
confidence: 99%